# NVS catalysts: NOVARTIS AG PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/nvs/catalysts

> NOVARTIS AG (NVS) has 202 upcoming catalysts. The next is the AAA617 primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, year only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | NOVARTIS AG |
| Ticker | NVS (NYSE) |
| SEC CIK | 1114448 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/nvs |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 1, 2016 | [Netspot (gallium dotatate ga-68) FDA approval](https://sec-api.dev/pdufa/gallium-dotatate-ga-68) | NVS |  | completed, approved | "NDA208547 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20160601, review_priority PRIORITY; sponsor_name NOVARTIS; product NETSPOT (GALLIUM DOTATATE GA-68)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208547%22)) |
| March 13, 2017 | [KISQALI® (ribociclib) FDA approval](https://sec-api.dev/pdufa/ribociclib) | NVS |  | completed, approved | "NDA209092 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170313, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22)) |
| April 28, 2017 | [Rydapt (midostaurin) FDA approval](https://sec-api.dev/pdufa/midostaurin) | NVS |  | completed, approved | "NDA207997 ORIG-2 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20170428, review_priority PRIORITY; sponsor_name NOVARTIS; product RYDAPT (MIDOSTAURIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207997%22)) |
| May 4, 2017 | [Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) FDA approval](https://sec-api.dev/pdufa/letrozole-ribociclib) | NVS |  | completed, approved | "NDA209935 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20170504, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22)) |
| May 18, 2017 | [Jadenu (deferasirox) FDA approval](https://sec-api.dev/pdufa/deferasirox) | NVS |  | completed, approved | "NDA207968 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20170518, review_priority STANDARD; sponsor_name NOVARTIS; product JADENU SPRINKLE (DEFERASIROX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207968%22)) |
| February 13, 2019 | [Egaten (triclabendazole) FDA approval](https://sec-api.dev/pdufa/triclabendazole) | NVS |  | completed, approved | "NDA208711 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190213, review_priority PRIORITY; sponsor_name NOVARTIS; product EGATEN (TRICLABENDAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208711%22)) |
| March 18, 2019 | [Zykadia (ceritinib) FDA approval](https://sec-api.dev/pdufa/ceritinib) | NVS |  | completed, approved | "NDA211225 ORIG-1: submission_status AP, submission_status_date 20190318, review_priority STANDARD; sponsor_name NOVARTIS; product ZYKADIA (CERITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA211225%22)) |
| March 26, 2019 | [Mayzent (siponimod) FDA approval](https://sec-api.dev/pdufa/siponimod) | NVS |  | completed, approved | "NDA209884 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190326, review_priority PRIORITY; sponsor_name NOVARTIS; product MAYZENT (SIPONIMOD)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209884%22)) |
| May 24, 2019 | [Piqray (alpelisib) FDA approval](https://sec-api.dev/pdufa/alpelisib) | NVS |  | completed, approved | "NDA212526 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20190524, review_priority PRIORITY; sponsor_name NOVARTIS; product PIQRAY (ALPELISIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212526%22)) |
| October 7, 2019 | [Beovu (brolucizumab-dbll) FDA approval](https://sec-api.dev/pdufa/brolucizumab-dbll) | NVS |  | completed, approved | "BLA761125 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191007, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product BEOVU (brolucizumab-dbll)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761125%22)) |
| November 15, 2019 | [Adakveo (crizanlizumab-tmca) FDA approval](https://sec-api.dev/pdufa/crizanlizumab-tmca) | NVS |  | completed, approved | "BLA761128 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20191115, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product ADAKVEO (CRIZANLIZUMAB-TMCA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761128%22)) |
| January 29, 2020 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-31 (Efficacy): submission_status AP, submission_status_date 20200129, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| May 6, 2020 | [TABRECTA (capmatinib) FDA approval](https://sec-api.dev/pdufa/capmatinib) | NVS |  | completed, approved | "NDA213591 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20200506, review_priority PRIORITY; sponsor_name NOVARTIS PHARM; product TABRECTA (CAPMATINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213591%22)) |
| June 16, 2020 | [Ilaris (canakinumab) label expansion decision](https://sec-api.dev/pdufa/canakinumab) | NVS |  | completed, approved | "BLA125319 SUPPL-97 (Efficacy): submission_status AP, submission_status_date 20200616, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS; product ILARIS (CANAKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125319%22)) |
| June 16, 2020 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20200616, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| July 6, 2020 | [Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) label expansion decision](https://sec-api.dev/pdufa/letrozole-ribociclib) | NVS |  | completed, approved | "NDA209935 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20200706, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22)) |
| July 6, 2020 | [KISQALI® (ribociclib) label expansion decision](https://sec-api.dev/pdufa/ribociclib) | NVS |  | completed, approved | "NDA209092 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20200706, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22)) |
| July 23, 2020 | [Jadenu (deferasirox) label expansion decision](https://sec-api.dev/pdufa/deferasirox) | NVS |  | completed, approved | "NDA206910 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20200723, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product JADENU (DEFERASIROX)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206910%22)) |
| August 20, 2020 | [Kesimpta (ofatumumab) label expansion decision](https://sec-api.dev/pdufa/ofatumumab) | NVS |  | completed, approved | "BLA125326 SUPPL-70 (Efficacy): submission_status AP, submission_status_date 20200820, review_priority PRIORITY; sponsor_name NOVARTIS; product KESIMPTA (OFATUMUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125326%22)) |
| November 24, 2020 | [Rydapt (midostaurin) label expansion decision](https://sec-api.dev/pdufa/midostaurin) | NVS |  | completed, approved | "NDA207997 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20201124, review_priority PRIORITY; sponsor_name NOVARTIS; product RYDAPT (MIDOSTAURIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207997%22)) |
| December 18, 2020 | [Leqvio (inclisiran sodium) complete response letter (CRL)](https://sec-api.dev/pdufa/inclisiran) | NVS |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22214012_2022_Orig1s000OtherActionLtrs.pdf%22)) |
| February 16, 2021 | [Entresto (sacubitril; valsartan) label expansion decision](https://sec-api.dev/pdufa/sacubitril-valsartan) | NVS |  | completed, approved | "NDA207620 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20210216, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product ENTRESTO (SACUBITRIL; VALSARTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207620%22)) |
| April 19, 2021 | [Diovan (valsartan) label expansion decision](https://sec-api.dev/pdufa/valsartan) | NVS |  | completed, approved | "NDA021283 SUPPL-58 (Efficacy): submission_status AP, submission_status_date 20210419, review_priority STANDARD; sponsor_name NOVARTIS; product DIOVAN (VALSARTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021283%22)) |
| May 28, 2021 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-43 (Efficacy): submission_status AP, submission_status_date 20210528, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| September 23, 2021 | [Tasigna (nilotinib hydrochloride) label expansion decision](https://sec-api.dev/pdufa/nilotinib) | NVS |  | completed, approved | "NDA022068 SUPPL-35 (Efficacy): submission_status AP, submission_status_date 20210923, review_priority PRIORITY; sponsor_name NOVARTIS; product TASIGNA (NILOTINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022068%22)) |
| October 29, 2021 | [Scemblix (asciminib) FDA approval](https://sec-api.dev/pdufa/asciminib) | NVS |  | completed, approved | "NDA215358 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211029, review_priority PRIORITY; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22)) |
| December 10, 2021 | [Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) label expansion decision](https://sec-api.dev/pdufa/letrozole-ribociclib) | NVS |  | completed, approved | "NDA209935 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20211210, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22)) |
| December 10, 2021 | [KISQALI® (ribociclib) label expansion decision](https://sec-api.dev/pdufa/ribociclib) | NVS |  | completed, approved | "NDA209092 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20211210, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22)) |
| December 22, 2021 | [Leqvio (inclisiran sodium) FDA approval](https://sec-api.dev/pdufa/inclisiran) | NVS |  | completed, approved | "NDA214012 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20211222, review_priority STANDARD; sponsor_name NOVARTIS; product LEQVIO (INCLISIRAN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214012%22)) |
| December 22, 2021 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-50 (Efficacy): submission_status AP, submission_status_date 20211222, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| December 30, 2021 | [Afinitor (everolimus) label expansion decision](https://sec-api.dev/pdufa/everolimus) | NVS |  | completed, approved | "NDA022334 SUPPL-50 (Efficacy): submission_status AP, submission_status_date 20211230, review_priority STANDARD; sponsor_name NOVARTIS; product AFINITOR (EVEROLIMUS)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022334%22)) |
| January 28, 2022 | [Tafinlar (dabrafenib mesylate) label expansion decision](https://sec-api.dev/pdufa/dabrafenib) | NVS |  | completed, approved | "NDA202806 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20220128, review_priority STANDARD; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22)) |
| January 28, 2022 | [Mekinist (trametinib dimethyl sulfoxide) label expansion decision](https://sec-api.dev/pdufa/trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA204114 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20220128, review_priority STANDARD; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204114%22)) |
| March 1, 2022 | [Mayzent (siponimod) label expansion decision](https://sec-api.dev/pdufa/siponimod) | NVS |  | completed, approved | "NDA209884 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220301, review_priority STANDARD; sponsor_name NOVARTIS; product MAYZENT (SIPONIMOD)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209884%22)) |
| March 23, 2022 | [Gozellix (gallium ga-68 gozetotide) FDA approval](https://sec-api.dev/pdufa/gallium-ga-68-gozetotide) | NVS |  | completed, approved | "NDA215841 ORIG-1 (Type 2 - New Active Ingredient): submission_status AP, submission_status_date 20220323, review_priority STANDARD; sponsor_name NOVARTIS; product LOCAMETZ (GALLIUM GA-68 GOZETOTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215841%22)) |
| March 23, 2022 | [Pluvicto (lutetium lu-177 vipivotide tetraxetan) FDA approval](https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan) | NVS |  | completed, approved | "Pluvicto \| lutetium (177Lu) vipivotide tetraxetan \| 3/23/2022 \| To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapiesDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022)) |
| April 5, 2022 | [Piqray (alpelisib) FDA approval](https://sec-api.dev/pdufa/alpelisib) | NVS |  | completed, approved | "NDA215039 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20220405, review_priority PRIORITY; sponsor_name NOVARTIS; product VIJOICE (ALPELISIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215039%22)) |
| May 27, 2022 | [Beovu (brolucizumab-dbll) label expansion decision](https://sec-api.dev/pdufa/brolucizumab-dbll) | NVS |  | completed, approved | "BLA761125 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20220527, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product BEOVU (brolucizumab-dbll)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761125%22)) |
| May 27, 2022 | [Tafinlar (dabrafenib mesylate) label expansion decision](https://sec-api.dev/pdufa/dabrafenib) | NVS |  | completed, approved | "NDA202806 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20220527, review_priority STANDARD; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22)) |
| May 27, 2022 | [Mekinist (trametinib dimethyl sulfoxide) label expansion decision](https://sec-api.dev/pdufa/trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA204114 SUPPL-23 (Efficacy): submission_status AP, submission_status_date 20220527, review_priority STANDARD; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204114%22)) |
| June 22, 2022 | [Tafinlar (dabrafenib mesylate) label expansion decision](https://sec-api.dev/pdufa/dabrafenib) | NVS |  | completed, approved | "NDA202806 SUPPL-22 (Efficacy): submission_status AP, submission_status_date 20220622, review_priority PRIORITY; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22)) |
| June 22, 2022 | [Mekinist (trametinib dimethyl sulfoxide) label expansion decision](https://sec-api.dev/pdufa/trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA204114 SUPPL-24 (Efficacy): submission_status AP, submission_status_date 20220622, review_priority PRIORITY; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204114%22)) |
| August 10, 2022 | [TABRECTA (capmatinib) label expansion decision](https://sec-api.dev/pdufa/capmatinib) | NVS |  | completed, approved | "NDA213591 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20220810, review_priority PRIORITY; sponsor_name NOVARTIS PHARM; product TABRECTA (CAPMATINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213591%22)) |
| October 3, 2022 | [Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) label expansion decision](https://sec-api.dev/pdufa/letrozole-ribociclib) | NVS |  | completed, approved | "NDA209935 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20221003, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22)) |
| October 3, 2022 | [KISQALI® (ribociclib) label expansion decision](https://sec-api.dev/pdufa/ribociclib) | NVS |  | completed, approved | "NDA209092 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20221003, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22)) |
| October 12, 2022 | [Scemblix (asciminib) label expansion decision](https://sec-api.dev/pdufa/asciminib) | NVS |  | completed, approved | "NDA215358 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20221012, review_priority PRIORITY; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22)) |
| November 22, 2022 | [Piqray (alpelisib) label expansion decision](https://sec-api.dev/pdufa/alpelisib) | NVS |  | completed, approved | "NDA212526 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20221122, review_priority STANDARD; sponsor_name NOVARTIS; product PIQRAY (ALPELISIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212526%22)) |
| March 16, 2023 | [Tafinlar (dabrafenib mesylate) FDA approval](https://sec-api.dev/pdufa/dabrafenib) | NVS |  | completed, approved | "NDA217514 ORIG-1 (New Combination and New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230316, review_priority PRIORITY; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217514%22)) |
| March 16, 2023 | [Tafinlar (dabrafenib mesylate) label expansion decision](https://sec-api.dev/pdufa/dabrafenib) | NVS |  | completed, approved | "NDA202806 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20230316, review_priority PRIORITY; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22)) |
| March 16, 2023 | [Mekinist (trametinib dimethyl sulfoxide) label expansion decision](https://sec-api.dev/pdufa/trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA204114 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20230316, review_priority PRIORITY; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204114%22)) |
| March 16, 2023 | [Mekinist (trametinib; trametinib dimethyl sulfoxide) FDA approval](https://sec-api.dev/pdufa/trametinib-trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA217513 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230316, review_priority PRIORITY; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB; TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217513%22)) |
| May 11, 2023 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-44 (Efficacy): submission_status AP, submission_status_date 20230511, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| August 25, 2023 | [Ilaris (canakinumab) label expansion decision](https://sec-api.dev/pdufa/canakinumab) | NVS |  | completed, approved | "BLA125319 SUPPL-107 (Efficacy): submission_status AP, submission_status_date 20230825, review_priority STANDARD; sponsor_name NOVARTIS PHARMS; product ILARIS (CANAKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125319%22)) |
| August 31, 2023 | [Tafinlar (dabrafenib mesylate) label expansion decision](https://sec-api.dev/pdufa/dabrafenib) | NVS |  | completed, approved | "NDA202806 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20230831, review_priority PRIORITY; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22)) |
| August 31, 2023 | [Mekinist (trametinib dimethyl sulfoxide) label expansion decision](https://sec-api.dev/pdufa/trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA204114 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20230831, review_priority PRIORITY; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204114%22)) |
| October 6, 2023 | [Cosentyx (secukinumab) FDA approval](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA761349 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20231006, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761349%22)) |
| October 31, 2023 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-63 (Efficacy): submission_status AP, submission_status_date 20231031, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| December 5, 2023 | [FABHALTA® (iptacopan) FDA approval](https://sec-api.dev/pdufa/iptacopan) | NVS | To treat paroxysmal nocturnal hemoglobinuria | completed, approved | "Fabhalta \| iptacopan \| 12/5/2023 \| To treat paroxysmal nocturnal hemoglobinuriaDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023)) |
| January 18, 2024 | [Piqray (alpelisib) label expansion decision](https://sec-api.dev/pdufa/alpelisib) | NVS |  | completed, approved | "NDA212526 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20240118, review_priority PRIORITY; sponsor_name NOVARTIS; product PIQRAY (ALPELISIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212526%22)) |
| April 12, 2024 | [Entresto (sacubitril; valsartan) FDA approval](https://sec-api.dev/pdufa/sacubitril-valsartan) | NVS |  | completed, approved | "NDA218591 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240412, review_priority STANDARD; sponsor_name NOVARTIS; product ENTRESTO SPRINKLE (SACUBITRIL; VALSARTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218591%22)) |
| April 12, 2024 | [Entresto (sacubitril; valsartan) label expansion decision](https://sec-api.dev/pdufa/sacubitril-valsartan) | NVS |  | completed, approved | "NDA207620 SUPPL-25 (Efficacy): submission_status AP, submission_status_date 20240412, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product ENTRESTO (SACUBITRIL; VALSARTAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA207620%22)) |
| April 24, 2024 | [Piqray (alpelisib) FDA approval](https://sec-api.dev/pdufa/alpelisib) | NVS |  | completed, approved | "NDA218466 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240424, review_priority STANDARD; sponsor_name NOVARTIS; product VIJOICE (ALPELISIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218466%22)) |
| April 24, 2024 | [Piqray (alpelisib) label expansion decision](https://sec-api.dev/pdufa/alpelisib) | NVS |  | completed, approved | "NDA215039 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20240424, review_priority STANDARD; sponsor_name NOVARTIS; product VIJOICE (ALPELISIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215039%22)) |
| June 26, 2024 | [Adakveo (crizanlizumab-tmca) label expansion decision](https://sec-api.dev/pdufa/crizanlizumab-tmca) | NVS |  | completed, approved | "BLA761128 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20240626, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product ADAKVEO (CRIZANLIZUMAB-TMCA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761128%22)) |
| July 22, 2024 | [KISQALI® (ribociclib) label expansion decision](https://sec-api.dev/pdufa/ribociclib) | NVS |  | completed, approved | "NDA209092 SUPPL-19 (Efficacy): submission_status AP, submission_status_date 20240722, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22)) |
| August 7, 2024 | [FABHALTA® (iptacopan) label expansion decision](https://sec-api.dev/pdufa/iptacopan) | NVS |  | completed, approved | "NDA218276 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20240807, review_priority PRIORITY; sponsor_name NOVARTIS; product FABHALTA (IPTACOPAN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218276%22)) |
| September 17, 2024 | [Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) label expansion decision](https://sec-api.dev/pdufa/letrozole-ribociclib) | NVS |  | completed, approved | "NDA209935 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20240917, review_priority STANDARD; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22)) |
| September 17, 2024 | [KISQALI® (ribociclib) label expansion decision](https://sec-api.dev/pdufa/ribociclib) | NVS |  | completed, approved | "NDA209092 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20240917, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22)) |
| October 29, 2024 | [Scemblix (asciminib) label expansion decision](https://sec-api.dev/pdufa/asciminib) | NVS |  | completed, approved | "NDA215358 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20241029, review_priority PRIORITY; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22)) |
| December 30, 2024 | [Onasemnogene abeparvovec topline data readout](https://sec-api.dev/pdufa/onasemnogene-abeparvovec) | NVS |  | completed, positive | "Basel, December 30, 2024 - Novartis today announced positive topline results from the" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1114448/000117184324007096/f6k_123024.htm)) |
| Mar 2025 | [FABHALTA® (iptacopan) FDA approval](https://sec-api.dev/pdufa/iptacopan) | NVS |  | completed, approved | "This is the third US approval received by Novartis for its kidney disease portfolio in the last year, with Fabhalta® having been granted FDA approval in C3 glomerulopathy (C3G) in March 2025 and accelerated approval in IgAN in August 202415." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1114448/000117184325001979/f6k_040325.htm)) |
| March 7, 2025 | [Tafinlar (dabrafenib mesylate) label expansion decision](https://sec-api.dev/pdufa/dabrafenib) | NVS |  | completed, approved | "NDA202806 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20250307, review_priority STANDARD; sponsor_name NOVARTIS; product TAFINLAR (DABRAFENIB MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA202806%22)) |
| March 7, 2025 | [Mekinist (trametinib dimethyl sulfoxide) label expansion decision](https://sec-api.dev/pdufa/trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA204114 SUPPL-34 (Efficacy): submission_status AP, submission_status_date 20250307, review_priority STANDARD; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204114%22)) |
| March 7, 2025 | [Mekinist (trametinib; trametinib dimethyl sulfoxide) label expansion decision](https://sec-api.dev/pdufa/trametinib-trametinib-dimethyl-sulfoxide) | NVS |  | completed, approved | "NDA217513 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20250307, review_priority STANDARD; sponsor_name NOVARTIS; product MEKINIST (TRAMETINIB; TRAMETINIB DIMETHYL SULFOXIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217513%22)) |
| March 20, 2025 | [FABHALTA® (iptacopan) label expansion decision](https://sec-api.dev/pdufa/iptacopan) | NVS |  | completed, approved | "NDA218276 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20250320, review_priority PRIORITY; sponsor_name NOVARTIS; product FABHALTA (IPTACOPAN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218276%22)) |
| March 28, 2025 | [Pluvicto (lutetium lu-177 vipivotide tetraxetan) label expansion decision](https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan) | NVS |  | completed, approved | "NDA215833 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20250328, review_priority STANDARD; sponsor_name NOVARTIS; product PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215833%22)) |
| April 2, 2025 | [Vanrafia® (atrasentan) FDA approval](https://sec-api.dev/pdufa/atrasentan) | NVS |  | completed, approved | "Vanrafia \| atrasentan \| 4/02/2025 \| To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progressionDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| May 7, 2025 | [Vay736 1ml pfs primary completion](https://sec-api.dev/pdufa/vay736) | NVS | Sjogren Syndrome | completed | "NCT05350072 (Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-07 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05350072)) |
| May 13, 2025 | [Vay736 1ml pfs primary completion](https://sec-api.dev/pdufa/vay736) | NVS | Sjogren Syndrome | completed | "NCT05349214 (Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-13 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05349214)) |
| May 15, 2025 | [Scemblix (asciminib) primary completion](https://sec-api.dev/pdufa/asciminib) | NVS | Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | completed | "NCT05456191 (A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-05-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05456191)) |
| May 21, 2025 | [PHE885 primary completion](https://sec-api.dev/pdufa/phe885) | NVS | Multiple Myeloma | withdrawn | "NCT05172596 (PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05172596)) |
| May 28, 2025 | [Lcz primary completion](https://sec-api.dev/pdufa/lcz) | NVS | Hypertension | completed | "NCT06236061 (Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06236061)) |
| June 19, 2025 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia | completed | "NCT05653219 (A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05653219)) |
| June 27, 2025 | [KLU156 primary completion](https://sec-api.dev/pdufa/klu156) | NVS | Uncomplicated Plasmodium Falciparum Malaria | completed | "NCT05842954 (Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05842954)) |
| June 30, 2025 | [Vanrafia® (atrasentan) primary completion](https://sec-api.dev/pdufa/atrasentan) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | completed | "NCT05834738 (Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05834738)) |
| July 24, 2025 | [Cipargamin primary completion](https://sec-api.dev/pdufa/cipargamin) | NVS | Severe Malaria | completed | "NCT04675931 (To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-04-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04675931)) |
| July 31, 2025 | [Leqvio (inclisiran sodium) label expansion decision](https://sec-api.dev/pdufa/inclisiran) | NVS |  | completed, approved | "NDA214012 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20250731, review_priority STANDARD; sponsor_name NOVARTIS; product LEQVIO (INCLISIRAN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214012%22)) |
| August 11, 2025 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | active Sjögren's disease | completed, positive | "Basel, August 11, 2025 - Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with active Sjögren's disease." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1114448/000117184325005290/f6k_081125.htm)) |
| August 13, 2025 | [Scemblix (asciminib) primary completion](https://sec-api.dev/pdufa/asciminib) | NVS | Chronic Myelogenous Leukemia - Chronic Phase | completed | "NCT05384587 (Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-13 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05384587)) |
| September 10, 2025 | [Brolucizumab 6mg primary completion](https://sec-api.dev/pdufa/brolucizumab) | NVS | Macular Polypoidal Choroidal Vasculopathy (PCV) | completed | "NCT05666804 (Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-10 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05666804)) |
| September 10, 2025 | [Cosentyx (secukinumab) primary completion](https://sec-api.dev/pdufa/secukinumab) | NVS | Polymyalgia Rheumatica | completed | "NCT05767034 (Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Polymyalgia Rheumatica (PMR)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-10 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05767034)) |
| September 17, 2025 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria | completed | "NCT06042478 (Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-09-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06042478)) |
| September 19, 2025 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | IgA Nephropathy | completed | "NCT04578834 (Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04578834)) |
| September 30, 2025 | [Rhapsido® (remibrutinib) FDA approval](https://sec-api.dev/pdufa/remibrutinib) | NVS |  | completed, approved | "Rhapsido \| remibrutinib \| 9/30/2025 \| To treat chronic spontaneous urticaria in adults who remain symptomatic despite H1 antihistamine treatmentDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| October 2, 2025 | [Scemblix (asciminib) label expansion decision](https://sec-api.dev/pdufa/asciminib) | NVS |  | completed, approved | "NDA215358 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251002, review_priority STANDARD; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22)) |
| October 14, 2025 | [MAS825 primary completion](https://sec-api.dev/pdufa/mas825) | NVS |  | completed | "NCT04641442 (Study to Evaluate the Efficacy, Safety and Tolerability of MAS825 in Patients With Monogenic IL-18 Driven Autoinflammatory Diseases, Including NLRC4-GOF, XIAP Deficiency, or CDC42 Mutations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04641442)) |
| October 15, 2025 | [Tasigna (nilotinib hydrochloride) primary completion](https://sec-api.dev/pdufa/nilotinib) | NVS | Chronic Myeloid Leukemia | withdrawn | "NCT03874858 (A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-10-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03874858)) |
| November 4, 2025 | [Kesimpta (ofatumumab) primary completion](https://sec-api.dev/pdufa/ofatumumab) | NVS | Multiple Sclerosis | completed | "NCT04788615 (Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-04 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04788615)) |
| November 24, 2025 | [Onasemnogene abeparvovec FDA approval](https://sec-api.dev/pdufa/onasemnogene-abeparvovec) | NVS |  | completed, approved | "Basel, November 24, 2025 - Novartis today announced that the US Food and Drug Administration (FDA) has approved" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1114448/000117184325007547/f6k_112425.htm)) |
| November 25, 2025 | [Scemblix (asciminib) label expansion decision](https://sec-api.dev/pdufa/asciminib) | NVS |  | completed, approved | "NDA215358 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20251125, review_priority STANDARD; sponsor_name NOVARTIS; product SCEMBLIX (ASCIMINIB HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215358%22)) |
| 2026 | [Zigakibart topline data readout](https://sec-api.dev/pdufa/zigakibart) | NVS |  | scheduled | "The Phase III BEYOND trial is ongoing with anticipated readout in 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1114448/000137036825000012/nvs-20250630-99_1.htm)) |
| 1H 2026 | [Pelabresib topline data readout](https://sec-api.dev/pdufa/pelabresib) | NVS |  | scheduled | "- Plan revised based on latest projections (event-driven trial); readout expected H1 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1114448/000137036825000007/a250131-99_2.htm)) |
| January 28, 2026 | [Ofatumumab approved dose primary completion](https://sec-api.dev/pdufa/ofatumumab-approved-dose) | NVS | Relapsing Multiple Sclerosis (RMS) | completed | "NCT06869785 (Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-01-28 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06869785)) |
| February 3, 2026 | [NGI226 primary completion](https://sec-api.dev/pdufa/ngi226) | NVS | Achilles Tendinopathy | completed | "NCT05592990 (A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-03 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05592990)) |
| February 12, 2026 | [Leqvio (inclisiran sodium) label expansion decision](https://sec-api.dev/pdufa/inclisiran) | NVS |  | completed, approved | "NDA214012 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260212, review_priority PRIORITY; sponsor_name NOVARTIS; product LEQVIO (INCLISIRAN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214012%22)) |
| February 17, 2026 | [Vay736 1ml pfs primary completion](https://sec-api.dev/pdufa/vay736) | NVS | Sjögrens Disease; Systemic Lupus Erythematosus; Rheumatoid Arthritis | completed | "NCT06293365 (Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-02-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06293365)) |
| February 20, 2026 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Warm Autoimmune Hemolytic Anemia (wAIHA) | completed | "NCT05648968 (A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-20 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05648968)) |
| February 24, 2026 | [Cosentyx (secukinumab) primary completion](https://sec-api.dev/pdufa/secukinumab) | NVS | Giant Cell Arteritis | completed | "NCT05380453 (Efficacy and Safety of Secukinumab in Patients With New Onset of Giant Cell Arteritis Who Are in Clinical Remission): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-02-24 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05380453)) |
| February 25, 2026 | [Tin816 70 mg lyophilisate powder primary completion](https://sec-api.dev/pdufa/tin816) | NVS | Acute Kidney Injury Due to Sepsis | completed | "NCT05996835 (Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-25 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05996835)) |
| March 12, 2026 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-91 (Efficacy): submission_status AP, submission_status_date 20260312, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| March 19, 2026 | [Iptacopan (part 1) primary completion](https://sec-api.dev/pdufa/iptacopan-part-1) | NVS | Lupus Nephritis | withdrawn | "NCT05268289 (Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-03-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05268289)) |
| March 25, 2026 | [Kesimpta (ofatumumab) primary completion](https://sec-api.dev/pdufa/ofatumumab) | NVS | Multiple Sclerosis (MS) | completed | "NCT04926818 (Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04926818)) |
| March 25, 2026 | [Pelacarsen primary completion](https://sec-api.dev/pdufa/pelacarsen) | NVS | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | completed | "NCT06267560 (Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06267560)) |
| April 9, 2026 | [Cipargamin topline data readout](https://sec-api.dev/pdufa/cipargamin) | NVS | Severe Malaria | completed | "NCT04675931 (To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-24 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-04-09." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04675931?tab=results)) |
| April 11, 2026 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Atypical Hemolytic Uremic Syndrome | completed | "NCT04889430 (Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-11 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04889430)) |
| April 17, 2026 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-97 (Efficacy): submission_status AP, submission_status_date 20260417, review_priority PRIORITY; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| May 11, 2026 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Inducible Urticaria | completed | "NCT05976243 (A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-05-11 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05976243)) |
| May 27, 2026 | [Scemblix (asciminib) topline data readout](https://sec-api.dev/pdufa/asciminib) | NVS | Philadelphia Chromosome-Positive Chronic Myeloid Leukemia | completed | "NCT05456191 (A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-05-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-05-27." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05456191?tab=results)) |
| June 2026 | [INE963 primary completion](https://sec-api.dev/pdufa/ine963) | NVS | Uncomplicated Plasmodium Falciparum Malaria | delayed | "NCT05750628 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-06-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05750628)) |
| June 17, 2026 | [INE963 primary completion](https://sec-api.dev/pdufa/ine963) | NVS | Uncomplicated Plasmodium Falciparum Malaria | completed | "NCT07811882 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B1)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811882)) |
| June 23, 2026 | [VHB937 primary completion](https://sec-api.dev/pdufa/vhb937) | NVS | Amyotrophic Lateral Sclerosis (ALS) | completed | "NCT06643481 (A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-06-23 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643481)) |
| 2H 2026 | [Desiran topline data readout](https://sec-api.dev/pdufa/desiran) | NVS |  | scheduled | "Del-desiran is currently being evaluated in the Phase III HARBOR study in DM1, with readout anticipated in H2 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1114448/000111444826000010/a260428-99_1.htm)) |
| July 1, 2026 | [Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate) label expansion decision](https://sec-api.dev/pdufa/letrozole-ribociclib) | NVS |  | completed, approved | "NDA209935 SUPPL-33 (Efficacy): submission_status AP, submission_status_date 20260701, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI FEMARA CO-PACK (COPACKAGED) (LETROZOLE; RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209935%22)) |
| July 1, 2026 | [KISQALI® (ribociclib) label expansion decision](https://sec-api.dev/pdufa/ribociclib) | NVS |  | completed, approved | "NDA209092 SUPPL-27 (Efficacy): submission_status AP, submission_status_date 20260701, review_priority PRIORITY; sponsor_name NOVARTIS; product KISQALI (RIBOCICLIB SUCCINATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209092%22)) |
| July 16, 2026 | [FABHALTA® (iptacopan) label expansion decision](https://sec-api.dev/pdufa/iptacopan) | NVS |  | completed, approved | "NDA218276 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20260716, review_priority PRIORITY; sponsor_name NOVARTIS; product FABHALTA (IPTACOPAN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218276%22)) |
| July 16, 2026 | [TQJ230 primary completion](https://sec-api.dev/pdufa/tqj230) | NVS | Cardiovascular Disease and Lipoprotein(a) | completed | "NCT04023552 (Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-07-16 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04023552)) |
| July 20, 2026 | [Vanrafia® (atrasentan) topline data readout](https://sec-api.dev/pdufa/atrasentan) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | completed | "NCT05834738 (Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-30 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05834738?tab=results)) |
| July 21, 2026 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Relapsing Multiple Sclerosis | completed | "NCT05147220 (Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-21 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05147220)) |
| July 22, 2026 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Relapsing Multiple Sclerosis | completed | "NCT05156281 (Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-22 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05156281)) |
| July 31, 2026 | [Pluvicto (lutetium lu-177 vipivotide tetraxetan) label expansion decision](https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan) | NVS |  | completed, approved | "NDA215833 SUPPL-37 (Efficacy): submission_status AP, submission_status_date 20260731, review_priority STANDARD; sponsor_name NOVARTIS; product PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215833%22)) |
| August 19, 2026 | [Iptacopan (lnp023) primary completion](https://sec-api.dev/pdufa/iptacopan-lnp023) | NVS | Age-Related Macular Degeneration | completed | "NCT05230537 (A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05230537)) |
| Aug to Nov 2026 | [Iptacopan (lnp023) topline data readout](https://sec-api.dev/pdufa/iptacopan-lnp023) | NVS | Age-Related Macular Degeneration | scheduled | "NCT05230537 (A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05230537)) |
| September 1, 2026 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS |  | completed, positive | "Basel, September 1, 2026 - Novartis today announced positive topline results from its Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis.1 Remibrutinib, a highly selective and potent oral Bruton's tyrosine kinase (BTK) inhibitor, demonstrated superiority versus teriflunomide in reducing annualized relapse rate (ARR) and inflammatory brain lesions with a favorable safety profile." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1114448/000117184326005824/f6k_090126.htm)) |
| September 3, 2026 | [JDQ443 primary completion](https://sec-api.dev/pdufa/jdq443) | NVS | Non-Small Cell Lung Cancer | withdrawn | "NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05132075)) |
| September 17, 2026 | [QCZ484 primary completion](https://sec-api.dev/pdufa/qcz484) | NVS | Hypertension | completed | "NCT06857955 (A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06857955)) |
| Sep to Dec 2026 | [QCZ484 topline data readout](https://sec-api.dev/pdufa/qcz484) | NVS | Hypertension | scheduled | "NCT06857955 (A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06857955)) |
| Oct 2026 to Jan 2027 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Coronary Artery Disease | scheduled | "NCT05360446 (Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05360446)) |
| October 6, 2026 | [Rhapsido® (remibrutinib) label expansion decision](https://sec-api.dev/pdufa/remibrutinib) | NVS |  | completed, approved | "NDA218436 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20261006, review_priority STANDARD; sponsor_name NOVARTIS; product RHAPSIDO (REMIBRUTINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218436%22)) |
| October 15, 2026 | [Pelacarsen primary completion](https://sec-api.dev/pdufa/pelacarsen) | NVS | Hyperlipoproteinemia (a) | withdrawn | "NCT05900141 (An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-10-15 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05900141)) |
| October 15, 2026 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA761349 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20261015, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761349%22)) |
| October 2026 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Coronary Artery Disease | delayed | "NCT05360446 (Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05360446)) |
| October 29, 2026 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia (ITP) | completed | "NCT05653349 (Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05653349)) |
| Oct 2026 to Jan 2027 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia (ITP) | scheduled | "NCT05653349 (Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-29 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05653349)) |
| Nov 2026 to Feb 2027 | [Lou064 (blinded) topline data readout](https://sec-api.dev/pdufa/lou064-blinded) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT05677451 (24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05677451)) |
| Nov 2026 to Feb 2027 | [Pluvicto topline data readout](https://sec-api.dev/pdufa/pluvicto) | NVS | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06004661 (Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-06 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06004661)) |
| Nov 2026 to Feb 2027 | [AAA617 topline data readout](https://sec-api.dev/pdufa/aaa617) | NVS | Metastatic Castration Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06894511 (An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06894511)) |
| November 2026 | [Lou064 (blinded) primary completion](https://sec-api.dev/pdufa/lou064-blinded) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT05677451 (24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05677451)) |
| November 4, 2026 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | IgA Nephropathy | completed | "NCT04578834 (Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04578834?tab=results)) |
| November 4, 2026 | [KLU156 topline data readout](https://sec-api.dev/pdufa/klu156) | NVS | Uncomplicated Plasmodium Falciparum Malaria | completed | "NCT05842954 (Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals; Results First Posted 2026-11-04." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05842954?tab=results)) |
| November 2026 | [Pluvicto primary completion](https://sec-api.dev/pdufa/pluvicto) | NVS | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06004661 (Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-06 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06004661)) |
| November 2026 | [AAA617 primary completion](https://sec-api.dev/pdufa/aaa617) | NVS | Metastatic Castration Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06894511 (An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06894511)) |
| Dec 2026 to Mar 2027 | [AAA617 topline data readout](https://sec-api.dev/pdufa/aaa617) | NVS | Prostatic Neoplasm | scheduled | "NCT05849298 (A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05849298)) |
| Dec 2026 to Mar 2027 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | scheduled | "NCT06388941 (Iptacopan in Patients With ANCA Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388941)) |
| Dec 2026 to Mar 2027 | [Luxdegalutamide topline data readout](https://sec-api.dev/pdufa/luxdegalutamide) | NVS | Metastatic Hormone-sensitive Prostate Cancer | scheduled | "NCT06991556 (An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991556)) |
| December 2026 | [Luxdegalutamide primary completion](https://sec-api.dev/pdufa/luxdegalutamide) | NVS | Metastatic Hormone-sensitive Prostate Cancer | scheduled | "NCT06991556 (An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991556)) |
| December 2026 | [AAA617 primary completion](https://sec-api.dev/pdufa/aaa617) | NVS | Prostatic Neoplasm | scheduled | "NCT05849298 (A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05849298)) |
| December 2026 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | scheduled | "NCT06388941 (Iptacopan in Patients With ANCA Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388941)) |
| 1H 2027 | [Zigakibart topline data readout](https://sec-api.dev/pdufa/zigakibart) | NVS | IgAN, with readout | scheduled | "Zigakibart is currently being evaluated in the Phase III BEYOND study in adults with IgAN, with readout anticipated in H1 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1114448/000111444826000012/nvs-20260630-99_1.htm)) |
| Jan to Apr 2027 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Neoplasms | scheduled | "NCT04544189 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04544189)) |
| Jan to Apr 2027 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | C3G | scheduled | "NCT04817618 (Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04817618)) |
| Jan to Apr 2027 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Cancer | scheduled | "NCT05038735 (Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05038735)) |
| January 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Cancer | scheduled | "NCT05038735 (Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05038735)) |
| January 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Breast Neoplasms | scheduled | "NCT04544189 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04544189)) |
| January 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | C3G | scheduled | "NCT04817618 (Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04817618)) |
| February 2027 | [LEE011 primary completion](https://sec-api.dev/pdufa/lee011) | NVS |  | scheduled | "NCT02934568 (Ribociclib (LEE011) Rollover Study for Continued Access): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-01 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02934568)) |
| Feb to May 2027 | [LEE011 topline data readout](https://sec-api.dev/pdufa/lee011) | NVS |  | scheduled | "NCT02934568 (Ribociclib (LEE011) Rollover Study for Continued Access): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-01 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02934568)) |
| Feb to May 2027 | [Afinitor (everolimus) topline data readout](https://sec-api.dev/pdufa/everolimus) | NVS | Tuberous Sclerosis Complex | scheduled | "NCT02962414 (Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02962414)) |
| Feb to May 2027 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | Advanced HER2+Breast Cancer | scheduled | "NCT04208178 (Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04208178)) |
| Feb to May 2027 | [KISQALI® (ribociclib) topline data readout](https://sec-api.dev/pdufa/ribociclib) | NVS | Melanoma | scheduled | "NCT04417621 (Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04417621)) |
| Feb to May 2027 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | Advanced Breast Cancer | scheduled | "NCT04524000 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04524000)) |
| Feb to May 2027 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria (CSU) | scheduled | "NCT06868212 (A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868212)) |
| Feb to May 2027 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Acute Coronary Syndrome | scheduled | "NCT07102628 (Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07102628)) |
| Feb to May 2027 | [Cipargamin topline data readout](https://sec-api.dev/pdufa/cipargamin) | NVS | Uncomplicated Plasmodium Falciparum Malaria | scheduled | "NCT07811908 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-04 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811908)) |
| February 2027 | [KISQALI® (ribociclib) primary completion](https://sec-api.dev/pdufa/ribociclib) | NVS | Melanoma | scheduled | "NCT04417621 (Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04417621)) |
| February 2027 | [Cipargamin primary completion](https://sec-api.dev/pdufa/cipargamin) | NVS | Uncomplicated Plasmodium Falciparum Malaria | scheduled | "NCT07811908 (Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-02-04 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811908)) |
| February 2027 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Acute Coronary Syndrome | scheduled | "NCT07102628 (Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02-11 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07102628)) |
| February 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria (CSU) | scheduled | "NCT06868212 (A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868212)) |
| February 2027 | [Afinitor (everolimus) primary completion](https://sec-api.dev/pdufa/everolimus) | NVS | Tuberous Sclerosis Complex | scheduled | "NCT02962414 (Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02962414)) |
| February 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Advanced HER2+Breast Cancer | scheduled | "NCT04208178 (Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04208178)) |
| February 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Advanced Breast Cancer | scheduled | "NCT04524000 (Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04524000)) |
| Mar to Jun 2027 | [Tisagenlecleucel topline data readout](https://sec-api.dev/pdufa/tisagenlecleucel) | NVS | B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma | scheduled | "NCT04094311 (Study of Out of Specification for Tisagenlecleucel): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04094311)) |
| Mar to Jun 2027 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05639114 (Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05639114)) |
| Mar to Jun 2027 | [EDI048 topline data readout](https://sec-api.dev/pdufa/edi048) | NVS | Cryptosporidiosis | scheduled | "NCT07249463 (Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07249463)) |
| March 2027 | [EDI048 primary completion](https://sec-api.dev/pdufa/edi048) | NVS | Cryptosporidiosis | scheduled | "NCT07249463 (Study Testing the Efficacy, Safety, and Tolerability of EDI048 in Cryptosporidium Infection Model in Healthy Adults): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07249463)) |
| March 2027 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05639114 (Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05639114)) |
| March 2027 | [Tisagenlecleucel primary completion](https://sec-api.dev/pdufa/tisagenlecleucel) | NVS | B-cell Acute Lymphoblastic Leukemia; Diffuse Large B-cell Lymphoma | scheduled | "NCT04094311 (Study of Out of Specification for Tisagenlecleucel): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04094311)) |
| Apr to Jul 2027 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05624749 (Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624749)) |
| Apr to Jul 2027 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06517758 (A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06517758)) |
| Apr to Jul 2027 | [Arumakimig topline data readout](https://sec-api.dev/pdufa/arumakimig) | NVS | Still´s Disease | scheduled | "NCT07203001 (A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07203001)) |
| Apr to Jul 2027 | [DII235 topline data readout](https://sec-api.dev/pdufa/dii235) | NVS | Lipoprotein Disorder | scheduled | "NCT07235046 (A Study of DII235 in Adults With Elevated Lipoprotein(a)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07235046)) |
| Apr to Jul 2027 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Hypercholesterolaemia | scheduled | "NCT07610278 (A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07610278)) |
| April 2027 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Systemic Lupus Erythematosus | scheduled | "NCT05624749 (Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624749)) |
| April 2027 | [Arumakimig primary completion](https://sec-api.dev/pdufa/arumakimig) | NVS | Still´s Disease | scheduled | "NCT07203001 (A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07203001)) |
| April 2027 | [DII235 primary completion](https://sec-api.dev/pdufa/dii235) | NVS | Lipoprotein Disorder | scheduled | "NCT07235046 (A Study of DII235 in Adults With Elevated Lipoprotein(a)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-04-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07235046)) |
| April 2027 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Hypercholesterolaemia | scheduled | "NCT07610278 (A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-04-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07610278)) |
| April 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06517758 (A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06517758)) |
| May to Aug 2027 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Atherosclerotic Cardiovascular Disease | scheduled | "NCT05030428 (Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05030428)) |
| May to Aug 2027 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06799000 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06799000)) |
| May to Aug 2027 | [GIA632 topline data readout](https://sec-api.dev/pdufa/gia632) | NVS | Atopic Dermatitis | scheduled | "NCT07220577 (Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220577)) |
| May 2027 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Atherosclerotic Cardiovascular Disease | scheduled | "NCT05030428 (Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05030428)) |
| May 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06799000 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06799000)) |
| May 2027 | [GIA632 primary completion](https://sec-api.dev/pdufa/gia632) | NVS | Atopic Dermatitis | scheduled | "NCT07220577 (Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07220577)) |
| Jun to Sep 2027 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | PIK3CA-related Overgrowth Spectrum (PROS) | scheduled | "NCT04980833 (Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04980833)) |
| Jun to Sep 2027 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06840392 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06840392)) |
| June 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Hidradenitis Suppurativa | scheduled | "NCT06840392 (A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-06-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06840392)) |
| June 2027 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | PIK3CA-related Overgrowth Spectrum (PROS) | scheduled | "NCT04980833 (Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-06-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04980833)) |
| Jul to Oct 2027 | [TABRECTA (capmatinib) topline data readout](https://sec-api.dev/pdufa/capmatinib) | NVS | Advanced Solid Tumors Which Are cMET-dependent | scheduled | "NCT03040973 (Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03040973)) |
| Jul to Oct 2027 | [Qbrexza (glycopyrronium tosylate) topline data readout](https://sec-api.dev/pdufa/glycopyrronium) | NVS | Asthma | scheduled | "NCT05222529 (Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05222529)) |
| Jul to Oct 2027 | [EYU688 topline data readout](https://sec-api.dev/pdufa/eyu688) | NVS | Dengue | scheduled | "NCT06006559 (A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06006559)) |
| Jul to Oct 2027 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | Diffuse Cutaneous Systemic Sclerosis | scheduled | "NCT06470048 (A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470048)) |
| Jul to Oct 2027 | [LXE408 topline data readout](https://sec-api.dev/pdufa/lxe408) | NVS | Chagas Disease | scheduled | "NCT06632600 (A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06632600)) |
| Jul to Oct 2027 | [Luxdegalutamide topline data readout](https://sec-api.dev/pdufa/luxdegalutamide) | NVS | Prostatic Cancer, Castration-Resistant | scheduled | "NCT07047118 (A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-16 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07047118)) |
| Jul to Oct 2027 | [GXV813 topline data readout](https://sec-api.dev/pdufa/gxv813) | NVS | Schizophrenia | scheduled | "NCT07467993 (Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07467993)) |
| July 2027 | [Luxdegalutamide primary completion](https://sec-api.dev/pdufa/luxdegalutamide) | NVS | Prostatic Cancer, Castration-Resistant | scheduled | "NCT07047118 (A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-16 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07047118)) |
| July 2027 | [EYU688 primary completion](https://sec-api.dev/pdufa/eyu688) | NVS | Dengue | scheduled | "NCT06006559 (A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06006559)) |
| July 2027 | [LXE408 primary completion](https://sec-api.dev/pdufa/lxe408) | NVS | Chagas Disease | scheduled | "NCT06632600 (A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06632600)) |
| July 2027 | [GXV813 primary completion](https://sec-api.dev/pdufa/gxv813) | NVS | Schizophrenia | scheduled | "NCT07467993 (Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07467993)) |
| July 2027 | [TABRECTA (capmatinib) primary completion](https://sec-api.dev/pdufa/capmatinib) | NVS | Advanced Solid Tumors Which Are cMET-dependent | scheduled | "NCT03040973 (Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03040973)) |
| July 2027 | [Qbrexza (glycopyrronium tosylate) primary completion](https://sec-api.dev/pdufa/glycopyrronium) | NVS | Asthma | scheduled | "NCT05222529 (Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05222529)) |
| July 2027 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Diffuse Cutaneous Systemic Sclerosis | scheduled | "NCT06470048 (A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06470048)) |
| Aug to Nov 2027 | [Zigakibart topline data readout](https://sec-api.dev/pdufa/zigakibart) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | scheduled | "NCT05852938 (A Study of Zigakibart in Adults With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-10 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05852938)) |
| Aug to Nov 2027 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS |  | scheduled | "NCT06865651 (Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06865651)) |
| Aug to Nov 2027 | [YMI024 topline data readout](https://sec-api.dev/pdufa/ymi024) | NVS | Coronary Artery Disease | scheduled | "NCT07830719 (Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-15 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830719)) |
| August 2027 | [Zigakibart primary completion](https://sec-api.dev/pdufa/zigakibart) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | scheduled | "NCT05852938 (A Study of Zigakibart in Adults With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-10 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05852938)) |
| August 2027 | [YMI024 primary completion](https://sec-api.dev/pdufa/ymi024) | NVS | Coronary Artery Disease | scheduled | "NCT07830719 (Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-15 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07830719)) |
| August 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS |  | scheduled | "NCT06865651 (Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-08-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06865651)) |
| Sep to Dec 2027 | [Ianalumab s.c. q4w topline data readout](https://sec-api.dev/pdufa/ianalumab-s-c-q4w) | NVS | Lupus Nephritis | scheduled | "NCT05126277 (Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05126277)) |
| Sep to Dec 2027 | [PKN605 topline data readout](https://sec-api.dev/pdufa/pkn605) | NVS | Atrial Fibrillation | scheduled | "NCT07217067 (A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217067)) |
| September 2027 | [PKN605 primary completion](https://sec-api.dev/pdufa/pkn605) | NVS | Atrial Fibrillation | scheduled | "NCT07217067 (A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-09-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07217067)) |
| September 2027 | [Ianalumab s.c. q4w primary completion](https://sec-api.dev/pdufa/ianalumab-s-c-q4w) | NVS | Lupus Nephritis | scheduled | "NCT05126277 (Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05126277)) |
| Oct 2027 to Jan 2028 | [CTL019 topline data readout](https://sec-api.dev/pdufa/ctl019) | NVS | B-Cell Acute Lymphoblastic Leukemia | scheduled | "NCT03876769 (Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03876769)) |
| Oct 2027 to Jan 2028 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT04747613 (Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04747613)) |
| October 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT04747613 (Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04747613)) |
| October 2027 | [CTL019 primary completion](https://sec-api.dev/pdufa/ctl019) | NVS | B-Cell Acute Lymphoblastic Leukemia | scheduled | "NCT03876769 (Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03876769)) |
| Nov 2027 to Feb 2028 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | Glomerulonephritis, IGA; Immunoglobulin A Nephropathy | scheduled | "NCT06797518 (Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06797518)) |
| November 2027 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Glomerulonephritis, IGA; Immunoglobulin A Nephropathy | scheduled | "NCT06797518 (Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06797518)) |
| Dec 2027 to Mar 2028 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Papulopustular Rosacea | scheduled | "NCT07681271 (A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07681271)) |
| December 2027 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Papulopustular Rosacea | scheduled | "NCT07681271 (A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07681271)) |
| Feb to May 2028 | [Decitabine topline data readout](https://sec-api.dev/pdufa/decitabine) | NVS | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic | scheduled | "NCT05201066 (Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05201066)) |
| February 2028 | [QMF149 primary completion](https://sec-api.dev/pdufa/qmf149) | NVS | Asthma | scheduled | "NCT05562466 (A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-01 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05562466)) |
| Feb to May 2028 | [QMF149 topline data readout](https://sec-api.dev/pdufa/qmf149) | NVS | Asthma | scheduled | "NCT05562466 (A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-02-01 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05562466)) |
| Feb to May 2028 | [Rapcabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT06581198 (A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06581198)) |
| Feb to May 2028 | [Remibrutinib (blinded) topline data readout](https://sec-api.dev/pdufa/remibrutinib-blinded) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06744920 (A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06744920)) |
| Feb to May 2028 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Atherosclerotic Cardiovascular Disease (ASCVD) | scheduled | "NCT06813911 (Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06813911)) |
| February 2028 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Atherosclerotic Cardiovascular Disease (ASCVD) | scheduled | "NCT06813911 (Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06813911)) |
| February 2028 | [Decitabine primary completion](https://sec-api.dev/pdufa/decitabine) | NVS | Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic | scheduled | "NCT05201066 (Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05201066)) |
| February 2028 | [Rapcabtagene autoleucel primary completion](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | Lupus Erythematosus, Systemic; Lupus Nephritis | scheduled | "NCT06581198 (A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-02-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06581198)) |
| February 2028 | [Remibrutinib (blinded) primary completion](https://sec-api.dev/pdufa/remibrutinib-blinded) | NVS | Generalized Myasthenia Gravis | scheduled | "NCT06744920 (A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-02-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06744920)) |
| Mar to Jun 2028 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Familial Hypercholesterolemia - Homozygous | scheduled | "NCT06597006 (Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06597006)) |
| Mar to Jun 2028 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Familial Hypercholesterolemia - Heterozygous | scheduled | "NCT06597019 (Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06597019)) |
| March 2028 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Familial Hypercholesterolemia - Homozygous | scheduled | "NCT06597006 (Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06597006)) |
| March 2028 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Familial Hypercholesterolemia - Heterozygous | scheduled | "NCT06597019 (Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06597019)) |
| Apr to Jul 2028 | [Vanrafia® (atrasentan) topline data readout](https://sec-api.dev/pdufa/atrasentan) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | scheduled | "NCT04573478 (Atrasentan in Patients With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04573478)) |
| Apr to Jul 2028 | [AAA617 topline data readout](https://sec-api.dev/pdufa/aaa617) | NVS | Oligometastatic Prostate Cancer (OMPC) | scheduled | "NCT05939414 (An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05939414)) |
| April 2028 | [Vanrafia® (atrasentan) primary completion](https://sec-api.dev/pdufa/atrasentan) | NVS | IgA Nephropathy; Immunoglobulin A Nephropathy | scheduled | "NCT04573478 (Atrasentan in Patients With IgA Nephropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-04-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04573478)) |
| April 2028 | [AAA617 primary completion](https://sec-api.dev/pdufa/aaa617) | NVS | Oligometastatic Prostate Cancer (OMPC) | scheduled | "NCT05939414 (An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05939414)) |
| May to Aug 2028 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | Lymphatic Malformations | scheduled | "NCT05948943 (Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05948943)) |
| May to Aug 2028 | [Cosentyx (secukinumab) topline data readout](https://sec-api.dev/pdufa/secukinumab) | NVS | Polymyalgia Rheumatica | scheduled | "NCT06331312 (Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06331312)) |
| May to Aug 2028 | [Pelabresib topline data readout](https://sec-api.dev/pdufa/pelabresib) | NVS |  | scheduled | "NCT07357727 (A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07357727)) |
| May to Aug 2028 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT07816328 (Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-24 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07816328)) |
| May 2028 | [Cosentyx (secukinumab) primary completion](https://sec-api.dev/pdufa/secukinumab) | NVS | Polymyalgia Rheumatica | scheduled | "NCT06331312 (Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-08 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06331312)) |
| May 2028 | [Pelabresib primary completion](https://sec-api.dev/pdufa/pelabresib) | NVS |  | scheduled | "NCT07357727 (A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07357727)) |
| May 2028 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Spontaneous Urticaria | scheduled | "NCT07816328 (Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-24 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07816328)) |
| May 2028 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | Lymphatic Malformations | scheduled | "NCT05948943 (Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-05-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05948943)) |
| Jun to Sep 2028 | [AAA817 topline data readout](https://sec-api.dev/pdufa/aaa817) | NVS | Prostate Cancer | scheduled | "NCT06780670 (Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06780670)) |
| Jun to Sep 2028 | [GIA632 topline data readout](https://sec-api.dev/pdufa/gia632) | NVS | Non-segmental Vitiligo | scheduled | "NCT07431177 (A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431177)) |
| June 2028 | [GIA632 primary completion](https://sec-api.dev/pdufa/gia632) | NVS | Non-segmental Vitiligo | scheduled | "NCT07431177 (A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-06-06 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07431177)) |
| June 2028 | [AAA817 primary completion](https://sec-api.dev/pdufa/aaa817) | NVS | Prostate Cancer | scheduled | "NCT06780670 (Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-06-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06780670)) |
| Jul to Oct 2028 | [Tisagenlecleucel topline data readout](https://sec-api.dev/pdufa/tisagenlecleucel) | NVS | Follicular Lymphoma (FL) | scheduled | "NCT05888493 (A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05888493)) |
| Jul to Oct 2028 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | Atypical Hemolytic Uremic Syndrome | scheduled | "NCT05935215 (Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05935215)) |
| July 2028 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Atypical Hemolytic Uremic Syndrome | scheduled | "NCT05935215 (Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05935215)) |
| July 2028 | [Tisagenlecleucel primary completion](https://sec-api.dev/pdufa/tisagenlecleucel) | NVS | Follicular Lymphoma (FL) | scheduled | "NCT05888493 (A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05888493)) |
| Sep to Dec 2028 | [Kesimpta (ofatumumab) topline data readout](https://sec-api.dev/pdufa/ofatumumab) | NVS | Relapsing Multiple Sclerosis | scheduled | "NCT03650114 (Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03650114)) |
| Sep to Dec 2028 | [AAA817 topline data readout](https://sec-api.dev/pdufa/aaa817) | NVS | Prostate Cancer | scheduled | "NCT06855277 (Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855277)) |
| Sep to Dec 2028 | [VHB937 topline data readout](https://sec-api.dev/pdufa/vhb937) | NVS | Alzheimer's Disease | scheduled | "NCT07094516 (A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-09-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07094516)) |
| Sep to Dec 2028 | [Vanrafia® (atrasentan) topline data readout](https://sec-api.dev/pdufa/atrasentan) | NVS | IgA Nephropathy (IgAN) | scheduled | "NCT07850752 (A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07850752)) |
| September 2028 | [VHB937 primary completion](https://sec-api.dev/pdufa/vhb937) | NVS | Alzheimer's Disease | scheduled | "NCT07094516 (A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-09-14 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07094516)) |
| September 2028 | [Vanrafia® (atrasentan) primary completion](https://sec-api.dev/pdufa/atrasentan) | NVS | IgA Nephropathy (IgAN) | scheduled | "NCT07850752 (A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA Nephropathy): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-09-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07850752)) |
| September 2028 | [AAA817 primary completion](https://sec-api.dev/pdufa/aaa817) | NVS | Prostate Cancer | scheduled | "NCT06855277 (Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-09-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06855277)) |
| September 2028 | [Kesimpta (ofatumumab) primary completion](https://sec-api.dev/pdufa/ofatumumab) | NVS | Relapsing Multiple Sclerosis | scheduled | "NCT03650114 (Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03650114)) |
| Oct 2028 to Jan 2029 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | IC-MPGN | scheduled | "NCT05755386 (Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05755386)) |
| October 2028 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | IC-MPGN | scheduled | "NCT05755386 (Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05755386)) |
| Nov 2028 to Feb 2029 | [Rapcabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | Scleroderma, Diffuse | scheduled | "NCT06655896 (Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06655896)) |
| Nov 2028 to Feb 2029 | [GHZ339 topline data readout](https://sec-api.dev/pdufa/ghz339) | NVS | Atopic Dermatitis | scheduled | "NCT06947993 (Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947993)) |
| Nov 2028 to Feb 2029 | [GIA632 topline data readout](https://sec-api.dev/pdufa/gia632) | NVS | Cutaneous Lichen Planus | scheduled | "NCT07775924 (A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775924)) |
| November 2028 | [GIA632 primary completion](https://sec-api.dev/pdufa/gia632) | NVS | Cutaneous Lichen Planus | scheduled | "NCT07775924 (A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07775924)) |
| November 2028 | [GHZ339 primary completion](https://sec-api.dev/pdufa/ghz339) | NVS | Atopic Dermatitis | scheduled | "NCT06947993 (Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-27 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06947993)) |
| November 2028 | [Rapcabtagene autoleucel primary completion](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | Scleroderma, Diffuse | scheduled | "NCT06655896 (Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06655896)) |
| Dec 2028 to Mar 2029 | [QVM149 topline data readout](https://sec-api.dev/pdufa/qvm149) | NVS | Asthma | scheduled | "NCT05776927 (A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05776927)) |
| Dec 2028 to Mar 2029 | [Octreotide lar topline data readout](https://sec-api.dev/pdufa/octreotide-lar) | NVS |  | scheduled | "NCT06784752 (Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-08 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06784752)) |
| Dec 2028 to Mar 2029 | [Arumakimig topline data readout](https://sec-api.dev/pdufa/arumakimig) | NVS | VEXAS Syndrome | scheduled | "NCT07748624 (A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07748624)) |
| Dec 2028 to Mar 2029 | [DDY391 topline data readout](https://sec-api.dev/pdufa/ddy391) | NVS | Moderate to Severe Psoriatic Arthritis | scheduled | "NCT07801495 (A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07801495)) |
| December 2028 | [Octreotide lar primary completion](https://sec-api.dev/pdufa/octreotide-lar) | NVS |  | scheduled | "NCT06784752 (Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-08 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06784752)) |
| December 2028 | [DDY391 primary completion](https://sec-api.dev/pdufa/ddy391) | NVS | Moderate to Severe Psoriatic Arthritis | scheduled | "NCT07801495 (A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-13 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07801495)) |
| December 2028 | [Arumakimig primary completion](https://sec-api.dev/pdufa/arumakimig) | NVS | VEXAS Syndrome | scheduled | "NCT07748624 (A 52-Week Study Evaluating the Efficacy and Safety of Arumakimig (MAS825) in Participants With VEXAS Followed by Open-Label Extension (OLE) Period): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-12-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07748624)) |
| December 2028 | [QVM149 primary completion](https://sec-api.dev/pdufa/qvm149) | NVS | Asthma | scheduled | "NCT05776927 (A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05776927)) |
| Jan to Apr 2029 | [Piqray (alpelisib) topline data readout](https://sec-api.dev/pdufa/alpelisib) | NVS | PIK3CA-related Overgrowth Spectrum (PROS) | scheduled | "NCT06997588 (EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06997588)) |
| Jan to Apr 2029 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia (ITP); Primary Evans Syndrome (ES) | scheduled | "NCT07421167 (A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07421167)) |
| January 2029 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Primary Immune Thrombocytopenia (ITP); Primary Evans Syndrome (ES) | scheduled | "NCT07421167 (A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07421167)) |
| January 2029 | [Piqray (alpelisib) primary completion](https://sec-api.dev/pdufa/alpelisib) | NVS | PIK3CA-related Overgrowth Spectrum (PROS) | scheduled | "NCT06997588 (EPIK-P4: A Phase II Single-arm Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum (PROS)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06997588)) |
| Feb to May 2029 | [Abl001/asciminib topline data readout](https://sec-api.dev/pdufa/abl001-asciminib) | NVS | Chronic Myeloid Leukemia (CML) | scheduled | "NCT06514534 (Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-02-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06514534)) |
| Feb to May 2029 | [DDY391 topline data readout](https://sec-api.dev/pdufa/ddy391) | NVS | Sjögren's Disease | scheduled | "NCT07737743 (A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-02-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07737743)) |
| Feb to May 2029 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Pruritus of Unknown Origin | scheduled | "NCT07811869 (A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811869)) |
| February 2029 | [Abl001/asciminib primary completion](https://sec-api.dev/pdufa/abl001-asciminib) | NVS | Chronic Myeloid Leukemia (CML) | scheduled | "NCT06514534 (Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-02-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06514534)) |
| February 2029 | [DDY391 primary completion](https://sec-api.dev/pdufa/ddy391) | NVS | Sjögren's Disease | scheduled | "NCT07737743 (A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-02-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07737743)) |
| February 2029 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Pruritus of Unknown Origin | scheduled | "NCT07811869 (A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-02-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07811869)) |
| Mar to Jun 2029 | [Rapcabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | Idiopathic Inflammatory Myopathies | scheduled | "NCT06665256 (Phase 2 Study of Rapcabtagene Autoleucel in Myositis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06665256)) |
| Mar to Jun 2029 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | IgE-Mediated Food Allergy; Peanut Allergy; Cow Milk Allergy | scheduled | "NCT07768371 (A 52-week Study of Remibrutinib in IgE-mediated Food Allergy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07768371)) |
| Mar to Jun 2029 | [NIO752 topline data readout](https://sec-api.dev/pdufa/nio752) | NVS |  | scheduled | "NCT07868328 (A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868328)) |
| March 2029 | [Rapcabtagene autoleucel primary completion](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | Idiopathic Inflammatory Myopathies | scheduled | "NCT06665256 (Phase 2 Study of Rapcabtagene Autoleucel in Myositis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-03-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06665256)) |
| March 2029 | [NIO752 primary completion](https://sec-api.dev/pdufa/nio752) | NVS |  | scheduled | "NCT07868328 (A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of NIO752 in Primary Tauopathies): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-03-26 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07868328)) |
| March 2029 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | IgE-Mediated Food Allergy; Peanut Allergy; Cow Milk Allergy | scheduled | "NCT07768371 (A 52-week Study of Remibrutinib in IgE-mediated Food Allergy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07768371)) |
| Apr to Jul 2029 | [Leqvio (inclisiran sodium) topline data readout](https://sec-api.dev/pdufa/inclisiran) | NVS | Primary Prevention of Atherosclerotic Cardiovascular Disease | scheduled | "NCT05739383 (A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-16 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05739383)) |
| April 2029 | [Leqvio (inclisiran sodium) primary completion](https://sec-api.dev/pdufa/inclisiran) | NVS | Primary Prevention of Atherosclerotic Cardiovascular Disease | scheduled | "NCT05739383 (A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-04-16 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05739383)) |
| May to Aug 2029 | [Rydapt (midostaurin) topline data readout](https://sec-api.dev/pdufa/midostaurin) | NVS | FLT3-mutated Acute Myeloid Leukemia | scheduled | "NCT03591510 (A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-05-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03591510)) |
| May 2029 | [Rydapt (midostaurin) primary completion](https://sec-api.dev/pdufa/midostaurin) | NVS | FLT3-mutated Acute Myeloid Leukemia | scheduled | "NCT03591510 (A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-05-18 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03591510)) |
| Jun to Sep 2029 | [Rapcabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | ANCA Associated Vasculitis (AAV) | scheduled | "NCT06868290 (Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-06-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868290)) |
| June 2029 | [Rapcabtagene autoleucel primary completion](https://sec-api.dev/pdufa/rapcabtagene-autoleucel) | NVS | ANCA Associated Vasculitis (AAV) | scheduled | "NCT06868290 (Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-06-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06868290)) |
| Jul to Oct 2029 | [Votoplam topline data readout](https://sec-api.dev/pdufa/votoplam) | NVS | Huntington Disease | scheduled | "NCT06254482 (An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-07-16 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06254482)) |
| Jul to Oct 2029 | [Crizanlizumab topline data readout](https://sec-api.dev/pdufa/crizanlizumab) | NVS | Sickle Cell Disease | scheduled | "NCT06439082 (A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06439082)) |
| Jul to Oct 2029 | [Remibrutinib oral treatment topline data readout](https://sec-api.dev/pdufa/remibrutinib-oral-treatment) | NVS | Relapsing Multiple Sclerosis | scheduled | "NCT06846281 (Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846281)) |
| Jul to Oct 2029 | [NOVARTIS AG topline data readout](https://sec-api.dev/companies/nvs/catalysts) | NVS | Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | scheduled | "NCT07498426 (A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07498426)) |
| July 2029 | [Crizanlizumab primary completion](https://sec-api.dev/pdufa/crizanlizumab) | NVS | Sickle Cell Disease | scheduled | "NCT06439082 (A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06439082)) |
| July 2029 | [Votoplam primary completion](https://sec-api.dev/pdufa/votoplam) | NVS | Huntington Disease | scheduled | "NCT06254482 (An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-07-16 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06254482)) |
| July 2029 | [NOVARTIS AG primary completion](https://sec-api.dev/companies/nvs/catalysts) | NVS | Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS) | scheduled | "NCT07498426 (A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-20 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07498426)) |
| July 2029 | [Remibrutinib oral treatment primary completion](https://sec-api.dev/pdufa/remibrutinib-oral-treatment) | NVS | Relapsing Multiple Sclerosis | scheduled | "NCT06846281 (Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-25 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06846281)) |
| Aug to Nov 2029 | [FWY003 topline data readout](https://sec-api.dev/pdufa/fwy003) | NVS | Geographic Atrophy Secondary to Age-related Macular Degeneration | scheduled | "NCT07441642 (A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441642)) |
| Aug to Nov 2029 | [Ianalumab topline data readout](https://sec-api.dev/pdufa/ianalumab) | NVS | Sjögren´s Disease | scheduled | "NCT07621809 (Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-15 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07621809)) |
| August 2029 | [Ianalumab primary completion](https://sec-api.dev/pdufa/ianalumab) | NVS | Sjögren´s Disease | scheduled | "NCT07621809 (Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom Burden): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-08-15 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07621809)) |
| August 2029 | [FWY003 primary completion](https://sec-api.dev/pdufa/fwy003) | NVS | Geographic Atrophy Secondary to Age-related Macular Degeneration | scheduled | "NCT07441642 (A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-08-21 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07441642)) |
| Sep to Dec 2029 | [KISQALI® (ribociclib) topline data readout](https://sec-api.dev/pdufa/ribociclib) | NVS | Early Breast Cancer | scheduled | "NCT05827081 (Phase IIIb Study of Ribociclib + ET in Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05827081)) |
| September 2029 | [KISQALI® (ribociclib) primary completion](https://sec-api.dev/pdufa/ribociclib) | NVS | Early Breast Cancer | scheduled | "NCT05827081 (Phase IIIb Study of Ribociclib + ET in Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-09-07 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05827081)) |
| Dec 2029 to Mar 2030 | [Pelabresib topline data readout](https://sec-api.dev/pdufa/pelabresib) | NVS | Hematologic Malignancy; Solid Tumor; Advanced Malignancies | scheduled | "NCT06401356 (An Extension Study for Patients Previously Enrolled in Studies With Pelabresib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06401356)) |
| Dec 2029 to Mar 2030 | [Rhapsido® (remibrutinib) topline data readout](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Pruritus of Unknown Origin | scheduled | "NCT07700056 (A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07700056)) |
| Dec 2029 to Mar 2030 | [DDY391 topline data readout](https://sec-api.dev/pdufa/ddy391) | NVS | Moderate to Severe Psoriatic Arthritis | scheduled | "NCT07923773 (Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-12-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07923773)) |
| December 2029 | [DDY391 primary completion](https://sec-api.dev/pdufa/ddy391) | NVS | Moderate to Severe Psoriatic Arthritis | scheduled | "NCT07923773 (Extension Study of Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic Arthritis (CDDY391A12201-extension)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-12-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07923773)) |
| December 2029 | [Rhapsido® (remibrutinib) primary completion](https://sec-api.dev/pdufa/remibrutinib) | NVS | Chronic Pruritus of Unknown Origin | scheduled | "NCT07700056 (A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-19 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07700056)) |
| December 2029 | [Pelabresib primary completion](https://sec-api.dev/pdufa/pelabresib) | NVS | Hematologic Malignancy; Solid Tumor; Advanced Malignancies | scheduled | "NCT06401356 (An Extension Study for Patients Previously Enrolled in Studies With Pelabresib): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06401356)) |
| Jan to Apr 2030 | [Pelacarsen (tqj230) topline data readout](https://sec-api.dev/pdufa/pelacarsen-tqj230) | NVS | Cardiovascular Disease and Lipoprotein(a) | scheduled | "NCT07517263 (An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-01-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07517263)) |
| January 2030 | [Pelacarsen (tqj230) primary completion](https://sec-api.dev/pdufa/pelacarsen-tqj230) | NVS | Cardiovascular Disease and Lipoprotein(a) | scheduled | "NCT07517263 (An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-01-09 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07517263)) |
| Mar to Jun 2030 | [Pelacarsen (tqj230) topline data readout](https://sec-api.dev/pdufa/pelacarsen-tqj230) | NVS | Aortic Stenosis | scheduled | "NCT05646381 (A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05646381)) |
| March 2030 | [Pelacarsen (tqj230) primary completion](https://sec-api.dev/pdufa/pelacarsen-tqj230) | NVS | Aortic Stenosis | scheduled | "NCT05646381 (A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05646381)) |
| Apr to Jul 2030 | [Votoplam (blinded) topline data readout](https://sec-api.dev/pdufa/votoplam-blinded) | NVS | Huntington Disease | scheduled | "NCT07326709 (A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07326709)) |
| April 2030 | [Votoplam (blinded) primary completion](https://sec-api.dev/pdufa/votoplam-blinded) | NVS | Huntington Disease | scheduled | "NCT07326709 (A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-04-02 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07326709)) |
| May to Aug 2030 | [KISQALI® (ribociclib) topline data readout](https://sec-api.dev/pdufa/ribociclib) | NVS | Early Breast Cancer | scheduled | "NCT03701334 (A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-05-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03701334)) |
| May 2030 | [KISQALI® (ribociclib) primary completion](https://sec-api.dev/pdufa/ribociclib) | NVS | Early Breast Cancer | scheduled | "NCT03701334 (A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-05-29 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03701334)) |
| Jun to Sep 2030 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | Primary Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT06994845 (Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06994845)) |
| June 2030 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Primary Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT06994845 (Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-06-28 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06994845)) |
| Jul to Oct 2030 | [Zigakibart topline data readout](https://sec-api.dev/pdufa/zigakibart) | NVS | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT07146906 (A Study to Assess the Effects of Zigakibart on IgA Nephropathy.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-07-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07146906)) |
| July 2030 | [Zigakibart primary completion](https://sec-api.dev/pdufa/zigakibart) | NVS | Immunoglobulin A Nephropathy (IgAN) | scheduled | "NCT07146906 (A Study to Assess the Effects of Zigakibart on IgA Nephropathy.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-07-12 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07146906)) |
| Oct 2030 to Jan 2031 | [Pacibekitug topline data readout](https://sec-api.dev/pdufa/pacibekitug) | NVS | Myocardial Infarction | scheduled | "NCT07938411 (A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-10-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07938411)) |
| October 2030 | [Pacibekitug primary completion](https://sec-api.dev/pdufa/pacibekitug) | NVS | Myocardial Infarction | scheduled | "NCT07938411 (A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-10-22 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07938411)) |

## Drugs

- [AAA617](https://sec-api.dev/pdufa/aaa617): Oligometastatic Prostate Cancer (OMPC), Prostatic Neoplasm, Metastatic Castration Resistant Prostate Cancer (mCRPC)
- [AAA817](https://sec-api.dev/pdufa/aaa817): Prostate Cancer
- [Abl001/asciminib](https://sec-api.dev/pdufa/abl001-asciminib): Chronic Myeloid Leukemia (CML)
- [Piqray (alpelisib)](https://sec-api.dev/pdufa/alpelisib): Advanced HER2+Breast Cancer, PIK3CA-related Overgrowth Spectrum (PROS), Lymphatic Malformations, Advanced Breast Cancer, Breast Cancer, Breast Neoplasms
- [Arumakimig](https://sec-api.dev/pdufa/arumakimig): Still´s Disease, VEXAS Syndrome
- [Scemblix (asciminib)](https://sec-api.dev/pdufa/asciminib): Chronic Myelogenous Leukemia - Chronic Phase, Philadelphia Chromosome-Positive Chronic Myeloid Leukemia
- [Vanrafia® (atrasentan)](https://sec-api.dev/pdufa/atrasentan): IgA Nephropathy, IgA Nephropathy (IgAN)
- [Brolucizumab 6mg](https://sec-api.dev/pdufa/brolucizumab): Macular Polypoidal Choroidal Vasculopathy (PCV)
- [Beovu (brolucizumab-dbll)](https://sec-api.dev/pdufa/brolucizumab-dbll): 
- [Ilaris (canakinumab)](https://sec-api.dev/pdufa/canakinumab): 
- [TABRECTA (capmatinib)](https://sec-api.dev/pdufa/capmatinib): Advanced Solid Tumors Which Are cMET-dependent
- [Zykadia (ceritinib)](https://sec-api.dev/pdufa/ceritinib): 
- [Cipargamin](https://sec-api.dev/pdufa/cipargamin): Severe Malaria, Uncomplicated Plasmodium Falciparum Malaria
- [Crizanlizumab](https://sec-api.dev/pdufa/crizanlizumab): Sickle Cell Disease
- [Adakveo (crizanlizumab-tmca)](https://sec-api.dev/pdufa/crizanlizumab-tmca): 
- [CTL019](https://sec-api.dev/pdufa/ctl019): B-Cell Acute Lymphoblastic Leukemia
- [Tafinlar (dabrafenib mesylate)](https://sec-api.dev/pdufa/dabrafenib): 
- [DDY391](https://sec-api.dev/pdufa/ddy391): Moderate to Severe Psoriatic Arthritis, Sjögren's Disease
- [Decitabine](https://sec-api.dev/pdufa/decitabine): Myelodysplastic Syndromes
- [Jadenu (deferasirox)](https://sec-api.dev/pdufa/deferasirox): 
- [Desiran](https://sec-api.dev/pdufa/desiran): 
- [DII235](https://sec-api.dev/pdufa/dii235): Lipoprotein Disorder
- [EDI048](https://sec-api.dev/pdufa/edi048): Cryptosporidiosis
- [Afinitor (everolimus)](https://sec-api.dev/pdufa/everolimus): Tuberous Sclerosis Complex
- [EYU688](https://sec-api.dev/pdufa/eyu688): Dengue
- [FWY003](https://sec-api.dev/pdufa/fwy003): Geographic Atrophy Secondary to Age-related Macular Degeneration
- [Netspot (gallium dotatate ga-68)](https://sec-api.dev/pdufa/gallium-dotatate-ga-68): 
- [GHZ339](https://sec-api.dev/pdufa/ghz339): Atopic Dermatitis
- [GIA632](https://sec-api.dev/pdufa/gia632): Atopic Dermatitis, Cutaneous Lichen Planus, Non-segmental Vitiligo
- [GXV813](https://sec-api.dev/pdufa/gxv813): Schizophrenia
- [Ianalumab](https://sec-api.dev/pdufa/ianalumab): active sjögren's disease, Diffuse Cutaneous Systemic Sclerosis, Systemic Lupus Erythematosus, Warm Autoimmune Hemolytic Anemia (wAIHA), Primary Immune Thrombocytopenia (ITP), Sjögren´s Disease, Primary Immune Thrombocytopenia
- [Ianalumab s.c. q4w](https://sec-api.dev/pdufa/ianalumab-s-c-q4w): Lupus Nephritis
- [Leqvio (inclisiran sodium)](https://sec-api.dev/pdufa/inclisiran): Acute Coronary Syndrome, Familial Hypercholesterolemia - Homozygous, Atherosclerotic Cardiovascular Disease (ASCVD), Atherosclerotic Cardiovascular Disease, Primary Prevention of Atherosclerotic Cardiovascular Disease, Hypercholesterolaemia, Familial Hypercholesterolemia - Heterozygous, Coronary Artery Disease
- [INE963](https://sec-api.dev/pdufa/ine963): Uncomplicated Plasmodium Falciparum Malaria
- [FABHALTA® (iptacopan)](https://sec-api.dev/pdufa/iptacopan): To treat paroxysmal nocturnal hemoglobinuria, Primary Immunoglobulin A Nephropathy (IgAN), Atypical Hemolytic Uremic Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis, IC-MPGN, IgA Nephropathy, Glomerulonephritis, IGA
- [Iptacopan (lnp023)](https://sec-api.dev/pdufa/iptacopan-lnp023): Age-Related Macular Degeneration
- [Iptacopan (part 1)](https://sec-api.dev/pdufa/iptacopan-part-1): Lupus Nephritis
- [JDQ443](https://sec-api.dev/pdufa/jdq443): Non-Small Cell Lung Cancer
- [KLU156](https://sec-api.dev/pdufa/klu156): Uncomplicated Plasmodium Falciparum Malaria
- [Lcz](https://sec-api.dev/pdufa/lcz): Hypertension
- [LEE011](https://sec-api.dev/pdufa/lee011): 
- [Kisqali Femara Co-Pack (Copackaged) (letrozole; ribociclib succinate)](https://sec-api.dev/pdufa/letrozole-ribociclib): 
- [Lou064 (blinded)](https://sec-api.dev/pdufa/lou064-blinded): Chronic Spontaneous Urticaria
- [Pluvicto (lutetium lu-177 vipivotide tetraxetan)](https://sec-api.dev/pdufa/lutetium-lu-177-vipivotide-tetraxetan): 
- [Luxdegalutamide](https://sec-api.dev/pdufa/luxdegalutamide): Prostatic Cancer, Castration-Resistant, Metastatic Hormone-sensitive Prostate Cancer
- [LXE408](https://sec-api.dev/pdufa/lxe408): Chagas Disease
- [MAS825](https://sec-api.dev/pdufa/mas825): 
- [Rydapt (midostaurin)](https://sec-api.dev/pdufa/midostaurin): FLT3-mutated Acute Myeloid Leukemia
- [NGI226](https://sec-api.dev/pdufa/ngi226): Achilles Tendinopathy
- [Tasigna (nilotinib hydrochloride)](https://sec-api.dev/pdufa/nilotinib): Chronic Myeloid Leukemia
- [NIO752](https://sec-api.dev/pdufa/nio752): Progressive Supranuclear Palsy
- [Octreotide lar](https://sec-api.dev/pdufa/octreotide-lar): Somatostatin Receptor Positive (SSTR+)
- [Kesimpta (ofatumumab)](https://sec-api.dev/pdufa/ofatumumab): Multiple Sclerosis (MS), Multiple Sclerosis, Relapsing Multiple Sclerosis
- [Ofatumumab approved dose](https://sec-api.dev/pdufa/ofatumumab-approved-dose): Relapsing Multiple Sclerosis (RMS)
- [Onasemnogene abeparvovec](https://sec-api.dev/pdufa/onasemnogene-abeparvovec): 
- [Pacibekitug](https://sec-api.dev/pdufa/pacibekitug): Myocardial Infarction
- [Pelabresib](https://sec-api.dev/pdufa/pelabresib): Hematologic Malignancy, Primary Myelofibrosis (PMF)
- [Pelacarsen](https://sec-api.dev/pdufa/pelacarsen): Hyperlipoproteinemia (a), Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease
- [Pelacarsen (tqj230)](https://sec-api.dev/pdufa/pelacarsen-tqj230): Cardiovascular Disease and Lipoprotein(a), Aortic Stenosis
- [PHE885](https://sec-api.dev/pdufa/phe885): Multiple Myeloma
- [PKN605](https://sec-api.dev/pdufa/pkn605): Atrial Fibrillation
- [Pluvicto](https://sec-api.dev/pdufa/pluvicto): Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- [QCZ484](https://sec-api.dev/pdufa/qcz484): Hypertension
- [QMF149](https://sec-api.dev/pdufa/qmf149): Asthma
- [QVM149](https://sec-api.dev/pdufa/qvm149): Asthma
- [Rapcabtagene autoleucel](https://sec-api.dev/pdufa/rapcabtagene-autoleucel): Idiopathic Inflammatory Myopathies, Lupus Erythematosus, Systemic, Scleroderma, Diffuse, ANCA Associated Vasculitis (AAV)
- [Rhapsido® (remibrutinib)](https://sec-api.dev/pdufa/remibrutinib): IgE-Mediated Food Allergy, Chronic Pruritus of Unknown Origin, Hidradenitis Suppurativa, Relapsing Multiple Sclerosis, Papulopustular Rosacea, Chronic Spontaneous Urticaria (CSU), Chronic Spontaneous Urticaria, Chronic Inducible Urticaria
- [Remibrutinib (blinded)](https://sec-api.dev/pdufa/remibrutinib-blinded): Generalized Myasthenia Gravis
- [Remibrutinib oral treatment](https://sec-api.dev/pdufa/remibrutinib-oral-treatment): Relapsing Multiple Sclerosis
- [KISQALI® (ribociclib)](https://sec-api.dev/pdufa/ribociclib): Early Breast Cancer, Melanoma
- [Entresto (sacubitril; valsartan)](https://sec-api.dev/pdufa/sacubitril-valsartan): 
- [Cosentyx (secukinumab)](https://sec-api.dev/pdufa/secukinumab): Polymyalgia Rheumatica, Giant Cell Arteritis
- [Mayzent (siponimod)](https://sec-api.dev/pdufa/siponimod): 
- [Tin816 70 mg lyophilisate powder](https://sec-api.dev/pdufa/tin816): Acute Kidney Injury Due to Sepsis
- [Tisagenlecleucel](https://sec-api.dev/pdufa/tisagenlecleucel): Follicular Lymphoma (FL), B-cell Acute Lymphoblastic Leukemia
- [TQJ230](https://sec-api.dev/pdufa/tqj230): Cardiovascular Disease and Lipoprotein(a)
- [Mekinist (trametinib dimethyl sulfoxide)](https://sec-api.dev/pdufa/trametinib-dimethyl-sulfoxide): 
- [Mekinist (trametinib; trametinib dimethyl sulfoxide)](https://sec-api.dev/pdufa/trametinib-trametinib-dimethyl-sulfoxide): 
- [Egaten (triclabendazole)](https://sec-api.dev/pdufa/triclabendazole): 
- [Diovan (valsartan)](https://sec-api.dev/pdufa/valsartan): 
- [Vay736 1ml pfs](https://sec-api.dev/pdufa/vay736): Sjogren Syndrome, Sjögrens Disease
- [VHB937](https://sec-api.dev/pdufa/vhb937): Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS)
- [Votoplam](https://sec-api.dev/pdufa/votoplam): Huntington Disease
- [Votoplam (blinded)](https://sec-api.dev/pdufa/votoplam-blinded): Huntington Disease
- [YMI024](https://sec-api.dev/pdufa/ymi024): Coronary Artery Disease
- [Zigakibart](https://sec-api.dev/pdufa/zigakibart): igan, with readout, IgA Nephropathy, Immunoglobulin A Nephropathy (IgAN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/nvs/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "NVS catalysts: NOVARTIS AG PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/nvs/catalysts

```bibtex
@misc{secapidev_companies_nvs_catalysts_20261116,
  title        = {NVS catalysts: NOVARTIS AG PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/nvs/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_nvs_catalysts_20261116","title":"NVS catalysts: NOVARTIS AG PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/nvs/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
